Levetiracetam Bluepharma (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilizes neuronal membranes and lowers neuronal excitability, thereby decreasing the likelihood of the synchronized firing that generates seizures.

The dosage of Levetiracetam Bluepharma is individualized by the prescribing healthcare professional based on factors such as the patient’s age, weight, renal function, seizure type and response to therapy. No fixed regimen is provided here.

Levetiracetam is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no well‑controlled studies in pregnant women. It may be used if the potential benefit outweighs any possible risk. Limited data are available for breastfeeding, so a risk‑benefit assessment is required.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with many older antiepileptics, levetiracetam has a relatively simple pharmacokinetic profile, minimal protein binding and few drug‑enzyme interactions. It is often chosen for its broad spectrum of activity and ease of titration, though individual response and tolerability vary among patients.

Levetiracetam Bluepharma should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, excessive heat and direct sunlight to maintain potency throughout its shelf life.

The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed.

Serious risks include severe allergic reactions, Stevens‑Johnson syndrome, suicidal thoughts or behaviors, major depression, and rare blood disorders such as neutropenia. Patients should be monitored closely for any new or worsening psychiatric symptoms or skin reactions.

Levetiracetam is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for patients with severe renal impairment, uncontrolled psychiatric illness, or those taking interacting medications listed under major interactions.